General lack of understanding of rare diseases, insufficient funding mechanisms and options, absence of legislative frameworks are but a few reasons the Asian orphan drugs market has seen minimal advancements. A sustainable access program through improved healthcare policies to protect the rare disease patients, and also to incentivize orphan drug developers, will help put an end to the market’s stagnant phase.
We’ve compiled a list of 10 superheroes behind the scenes who’ve been pushing for more patient rights protection, healthcare policy revision, and public awareness of rare diseases in their individual state or country in Asia in an e-book. We introduce to you 10 inspirational figures who will further encourage industry peers to push for greater access of orphan drugs in Asia, and better coverage of drugs pricing and health insurance.
Several of these inspirational figures will be joining us at World Orphan Drugs Congress Asia, held this 3-4 June in Singapore. Find out more